Publications by authors named "Alex Schepart"
Patients with triple-class refractory (TCR) multiple myeloma (MM) have limited treatment options and poor prognoses. This high unmet need has prompted the development of new therapies allowing for improved outcomes for these patients. Recently, new targeted therapies for the treatment of patients with relapsed or refractory MM have been approved based on single-arm clinical trial results.
View Article and Find Full Text PDFArticle Synopsis
- - In the MagnetisMM-3 trial, the efficacy of elranatamab was compared to physician's choice treatment for patients with triple-class refractory multiple myeloma, showing promising results for the new therapy.
- - Analysis of two oncology databases (COTA and Flatiron Health) revealed that patients treated with elranatamab had a higher objective response rate, longer progression-free survival, and better overall survival compared to those receiving standard physician-selected treatments.
- - Elranatamab demonstrated significant benefits for BCMA-naive patients, suggesting it may be a more effective option compared to treatments commonly used in clinical practice.
Article Synopsis
- For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), B-cell maturation antigen and CD3-directed bispecific antibodies like teclistamab and elranatamab are emerging as new treatment options due to limited existing therapies.
- Teclistamab received conditional approval in Europe and accelerated FDA approval based on the MajesTEC-1 trial, while elranatamab was approved by the FDA following the MagnetisMM-3 trial.
- An indirect comparison showed that elranatamab outperformed teclistamab in terms of objective response rate and progression-free survival, suggesting it may be a more effective treatment for TCE/RMM patients.
Article Synopsis
- - Elranatamab, a new bispecific antibody targeting BCMA and CD3, was approved in August 2023 for treating triple-class exposed/refractory multiple myeloma (TCE/R MM) and showed promising results in the Phase 2 MagnetisMM-3 trial.
- - A matching-adjusted indirect comparison (MAIC) was conducted to evaluate elranatamab's effectiveness against physician's choice of treatment (PCT) by adjusting patient data from MagnetisMM-3 to real-world data from LocoMMotion and MAMMOTH studies.
- - Results indicated elranatamab significantly outperformed PCT, showing higher objective response rates, complete response rates, and longer
This study describes real-world treatment patterns of Medicare beneficiaries with relapsed or refractory multiple myeloma (RRMM) who are triple class exposed (TCE). Retrospective analysis of Medicare fee for service claims to identify a cohort age >65 with RRMM + TCE, 1 January 2016 to 30 June 2019. Initiation of a new treatment regimen (TCE1), healthcare resource utilization, cost and mortality.
View Article and Find Full Text PDF